The single-dose immunizer uses the first component produced by Russia for immunization against the new coronavirus
The Russian Direct Investment Fund (RDIF) and the Gamaleia National Research Center for Epidemiology and Microbiology publish the results of the single-dose vaccine efficacy analysis “Sputnik Light“ against the infection of Delta variant of the new coronavirus. An article with the results was submitted to MedRxiv’s preprints portal for scientific articles in the field of medicine for publication this week. According to the material, the vaccine administered alone demonstrated 70% effectiveness against the Delta variant during the first three months after immunization. It is identified as 75% effective among individuals under 60 years of age. The use of the immunizing agent also offers greater protection against the severe form of Covid-19 and hospitalizations. The analysis was conducted based on data from 28,000 participants who received a single dose of “Sputnik Light” compared to a control group of 5.6 million individuals who were not vaccinated. The data used in the study were collected in July 2021 in Moscow.
“The efficacy indicators of the single-component ‘Sputnik Light’ vaccine against the Delta variant of the coronavirus significantly exceed those of a number of other drugs. Data from the Gamaleia Center, as well as studies around the world, confirm that today the ‘Sputnik Light’ vaccine is one of the best drugs against the coronavirus,” he said. Kirill Dmitriev, CEO of RDIF. The director of the Gamaleia Center, on the other hand, highlighted that the vaccine can be used to maintain herd immunity in societies. “The vaccine’s single-dose regimen makes it a strong solution for countries with low vaccination rates. ‘Sputnik Light’ can also be used successfully to maintain existing herd immunity as a booster injection,” he said. “Sputnik Light” is already authorized in more than 15 countries and is in the process of being registered in another 30.
The “Sputnik Light” vaccine is based on human adenovirus serotype 26, the first component of “Sputnik V” – the world’s first registered vaccine against coronavirus – and will be produced by RDIF’s international partners in more than 10 countries (India, China, South Korea, Vietnam, Mexico, Argentina, Serbia, Turkey, among others). This includes the Serum Institute of India, the world’s largest producer of vaccines.
*With information from Estadão Content